Articles tagged with Cancer Medication
Scientists at MIT have developed a screening method to study protein-protein interactions, which are crucial in understanding disease mechanisms. The researchers created a synthetic molecule that binds tightly to a protein implicated in cancer metastasis, providing a potential tool for disrupting disease-causing interactions.
Researchers at Rice University and Baylor College of Medicine have created an antibody with an engineered peptide that effectively targets and attacks bone tumors in breast cancer. The study shows the therapeutic efficacy is best when a moderate amount of the drug compound is delivered, offering new hope for treating bone metastases.
Researchers found that glioma cells with mutated ATRX have reduced Chk1 activity, leading to dysregulated cell cycle and heightened sensitivity to ATM inhibitors. The study suggests that combining radiation therapy with these inhibitors may improve treatment outcomes for patients with this gene mutation.
Four MUSC Hollings Cancer Center researchers received American Cancer Society Institutional Research Grants worth $35,000 each. The grants support promising projects that aim to push cancer care forward. Researchers are working on various innovative projects, including a digital literacy training program for community health workers an...
An international team led by the University of Ottawa has published findings on the importance of the enzyme GCN5 in maintaining muscle integrity. The study discovered that GCN5 plays a crucial role in boosting the expression of key structural proteins, notably dystrophin.
A study published in Clinical Cancer Research shows that matched targeted therapy according to ESCAT's ranking of genomic alterations significantly improves survival of cholangiocarcinoma patients. Patients with ESCAT tier I-II alterations had longer median overall survival compared to those with non-actionable alterations.
Researchers at VTC have developed a promising three-pronged approach to treating glioblastoma, a lethal brain cancer. By inhibiting two specific proteins with temozolomide, they created an effective 'triple combinational therapy' that overcame chemoresistance.
A new combination immune therapy treatment extends cancer patients' lives while reducing toxic side effects and improving their overall health. This study found that the treatment was less toxic than other drugs on the market, providing an added benefit for patients' quality of life.
Researchers identified a novel therapeutic target for multiple myeloma by discovering the Sec61 translocon's vulnerability to inhibition. This targets the translocon prevents multiple myeloma cells from producing proteins through the secretory pathway, leading to their death.
Researchers at Tufts University have found that manipulating voltage patterns in tumor cells can significantly reduce tumor cell invasion and metastasis in animal models. Using FDA-approved ion channel blockers, they were able to normalize cell voltages, decrease tumor growth, and limit the spread of cancer cells.
The first-in-human trial of CAR-M cell therapy demonstrated that engineered macrophages can target and alter the solid tumor microenvironment, altering the composition of myeloid cells and T-cells. This innovative immunotherapy offers a promising new strategy in the fight against cancer.
Researchers at RIKEN successfully treated cancer in mice using metal catalysts that assemble anticancer drugs inside the body. The technique avoids indiscriminate tissue damage and increases cancer-inhibiting activity by 1000 times.
Researchers have revealed mechanisms by which polyps develop into colorectal cancer, setting the stage for improved surveillance utilizing precision medicine. The study found that serrated polyps derive from metaplasia, an abnormal change of cells into non-native tissue.
Scientists develop hairy cellulose nanocrystals to capture and remove excess chemotherapy drugs from the blood. The nanocrystals effectively removed over 6,000 milligrams of doxorubicin per gram, increasing DOX capture by two to three orders of magnitude compared to existing methods.
Researchers found that 48% of patients experienced complete or partial response to pembrolizumab treatment, with two-thirds experiencing clinical response. The study suggests a potential for curative intent in patients with recurrent or metastatic uterine cancer.
Researchers developed a color-coded test that quickly signals whether medical nanoparticles deliver their cargo into target cells. The tool, tested in mouse cells and living mice, assesses nanoparticle formulations on their ability to escape cellular defenses and reach the cell's interior.
A portable prostate cancer screening kit could provide early warning to populations with higher incidence of prostate cancer, particularly African American men. The test uses a test strip and reader to quantify PSA from a drop of blood in minutes, delivering results in 10-15 minutes.
A study from Weill Cornell Medicine and Cornell University reveals that targeting protein ATF4 and its related metabolic protein SIRT3 can trick lymphoma cells into starving themselves, slowing their growth.
A clinical trial will harness synthetic chimeric antigen receptor (CAR) T cells to deplete immune B cells and plasma cells producing donor-specific antibodies, aiming to achieve a compatible kidney match for patients with pre-existing antibodies. The NIH-funded study, led by Penn Medicine, intends to begin enrolling patients in 2022.
A new post-surgery approach for treating HPV-related throat cancer uses low-dose radiation and spares the majority of patients from chemotherapy. The trial found high survival rates and quality of life in patients at medium risk for recurrence.
Researchers create plan for proactively developing drug cocktails against virus families, aiming to provide effective treatments in weeks, not months. The approach prioritizes combination therapy to reduce disease spread and limit viral adaptation.
Researchers developed a model of drug resistance in melanoma, revealing mechanisms involving extrachromosomal DNA amplifications and intrachromosomal chromosomal rearrangements. The study found that different forms of DNA offer 'fitness' advantages to tumor cells under varying therapeutic conditions.
The inaugural WHO classification of childhood tumors presents a single, updated compendium of all tumor entities in childhood or adolescence, divided by organ sites. This classification incorporates traditional morphology, immunohistochemistry, and molecular characteristics to provide essential criteria for definition of tumor types.
A clinical study and register studies have failed to confirm previous findings that a medicine blocking testosterone could help against COVID-19. The researchers found no discernible signs of the drug having any beneficial effect on participants' health status.
Researchers at Houston Methodist have discovered a new combination therapy that regresses tumor growth of triple negative breast cancer and prevents the cancer from spreading. The response rate using this therapy is about 50%, compared to 25-30% with older drugs, offering new hope for patients with hard-to-treat breast cancers.
Researchers have found that depleting copper levels in the body can greatly reduce the ability of cancer cells to metastasize, including aggressive breast cancer. The discovery provides hope for developing more effective treatments for high-risk triple-negative breast cancer.
The KEYNOTE-811 trial demonstrates a significant improvement in objective response rate (74.4%) and tumor size reduction compared to trastuzumab and chemotherapy. The combination of pembrolizumab, trastuzumab, and chemotherapy markedly reduces tumor size and induces complete responses in some patients.
A novel medical cooling system for preventing Chemotherapy-induced peripheral neuropathy (CIPN) is being developed by the University of Huddersfield and Paxman. CIPN causes pain or sensitivity in hands and feet, delaying treatment. The new device uses 'Human Centred Design' to deliver stable cooling, tolerable over chemotherapy duration.
Researchers have discovered that a common class of targeted therapies can help more colorectal cancer patients than previously thought. By analyzing cell studies and computer modeling, the team identified 10 distinct RAS mutations that do not preclude the use of EGFR inhibitors, which are already approved for other uses.
Cancer cells secrete type III collagen to stay dormant, and when levels decrease, they wake up and create metastatic cancer. Researchers found that enriching the environment with collagen can force cells to remain in a dormant state and prevent tumor recurrence.
Researchers have discovered that NOR-1 protein can provide broad protection against heart damage following cancer treatment. Administering the protein directly may reduce heart risk, at least in laboratory tests.
Researchers found a novel therapy called AVID200 safe and well-tolerated, with modest improvements in symptom burden, anemia, and spleen enlargement. The therapy needs to be combined with other drugs to optimize impact in patients.
Researchers identified three prototypical RNA-expression states in pancreatic cancer cells and found that altering the tumor microenvironment can drive tumor cells to become more susceptible to certain drugs. This discovery opens up new possibilities for personalized medicine and targeting specific drug responses.
IN8bio is developing a genetically modified gamma-delta T cell technology to treat glioblastoma multiforme. Preclinical studies published in Scientific Reports show significant improvement in survival outcomes, and a Phase I clinical trial is underway at UAB.
Investigators at Weill Cornell Medicine identified significant age-related differences in tumor characteristics across various cancers, suggesting potential for personalized treatment approaches. They found that tumors from younger patients showed advanced signs of aging and more mutations associated with aggressive disease.
A recent study by NTU Singapore and Singapore General Hospital found that mutations in the DDX3X gene are responsible for chemotherapy resistance in some blood cancer patients. The study also discovered that STAT inhibitors can effectively kill lymphoma cells with DDX3X mutations, providing hope for new treatment options.
A new protein variant called CLIP-170S allows cancer cells to dodge chemotherapy drugs, rendering them ineffective. Researchers discovered this variant in more than 60% of patients with gastric cancer and are exploring a combination therapy involving imatinib to overcome resistance.
A research team developed an AI framework that analyzes protein interactions to predict effective and low-toxicity cancer drug combinations. The framework, GraphSynergy, outperforms conventional models in identifying synergistic combinations.
A study by Weill Cornell Medicine scientists found that blocking a signaling pathway in brain immune cells can protect against Alzheimer's disease features in a preclinical model. The results suggest a new strategy to block the development of the disease or slow its progression.
A recent review article describes a class of viruses known as oncolytic viruses, which have the remarkable ability to target and destroy cancer cells. Researchers are exploring these viruses for cancer therapy, with some showing promising results in stimulating an immune response against cancer.
Researchers at the University of Gothenburg have successfully treated high-risk neuroblastoma in mice using a combination of precision medicines, showing potential for a curative treatment. The study's results suggest that patients with this form of childhood cancer may benefit from drug treatment with ATR inhibitors.
The AACR and Pelotonia launch a grants program to recognize five influential female researchers in breast and gynecologic cancers. Nomination deadlines are January 14, 2022, with awards presented at the AACR Annual Meeting 2022.
Researchers at Princeton University have discovered a new compound that can disable the MTDH gene, which is essential for cancer progression and metastasis. The compound shows promise in treating major human cancers, including breast, prostate, lung, and colon cancers.
Research found that proton pump inhibitors (PPIs) may reduce the effectiveness of immune checkpoint inhibitor drugs in patients with non-small-cell lung cancer. PPI use was associated with worse survival rates and a significant decrease in the benefit of immune therapy treatment.
Researchers found that second-generation antihistamines block histamine binding to HRH1, improving cytotoxic T cell activation and reducing resistance to immunotherapy. High plasma histamine levels in patients were correlated with worse responses to anti-PD-1 immunotherapy.
Researchers from the University of Copenhagen have discovered a natural substance, a flavonoid, that can inhibit cancer cells' ability to defend themselves against chemotherapy by targeting efflux pumps. This could lead to more effective treatment and potentially even combat antibiotic resistance.
Researchers at the University of Helsinki and Aalto University have developed a gel-grown mini-breast cancer model that can effectively treat hormone-dependent breast cancers. The discovery opens new avenues for hormonal therapies, individual drug responses, and drug resistance mechanisms.
Researchers discovered that chemotherapy drugs can affect protein synthesis in muscle cells, even at low doses. This finding has significant implications for cancer treatment and exercise rehabilitation programs, suggesting that even non-oxidative stress effects of chemotherapy should be considered.
Researchers developed a novel model to identify specific genes and genetic alterations in multiple myeloma, stratifying the cancer's severity via DNA and RNA sequencing. This model revealed diverse subtypes and high-risk patients beyond current classifications.
A functional precision medicine study demonstrates that treatment selection based on results from drug sensitivity testing can be clinically useful in patients with aggressive hematological cancer. The approach combines deep molecular profiling with comprehensive drug sensitivity testing to advance the therapy decision-making system.
Researchers have developed fish-shaped microrobots that can guide themselves to cancer cells using magnets, where a pH change opens their mouths to release chemotherapy. The microrobots demonstrate promising capabilities for targeted cancer treatment, but need further improvements in size and tracking methods.
A recent study published in JNCCN found that only 31% of hospitals have immediate availability of all-trans retinoic acid (ATRA), a crucial blood cancer medication. This medication is essential for treating acute promyelocytic leukemia, which has a better prognosis when treated appropriately. The lack of ATRA availability poses a signi...
A Mount Sinai study reveals that young adult cancer patients exhibit distinct genetic hallmarks and immune system responses compared to their older counterparts. These findings suggest personalized treatment approaches for young adults with various types of cancers.
A new study by the Regenstrief Institute found that lack of protocols or standard operating procedures in the recovery room is a significant barrier to administering post-operative chemotherapy to reduce bladder cancer recurrence. The researchers identified 58 Michigan urologists who reported this as a major obstacle, emphasizing the n...
Women with breast cancer are at a higher risk of developing atrial fibrillation and dying from heart-related issues within the first year. The condition was more common in women who did not receive surgery or radiation as their initial treatment.
Researchers at UVA Cancer Center discovered how a common gene mutation disrupts cells' ability to suppress tumors. The mutation in the UTX gene forms tiny droplets that help prevent tumor formation.
A Johns Hopkins-led study found that leptin cancels out the effects of Tamoxifen, making it ineffective for obese patients with breast cancer. Researchers suggest that interventions targeting leptin or Med1 may improve Tamoxifen's success in this group.
St. Jude researchers have identified a possible risk for late effects of treatment with the experimental cancer drug CX-5461, which targets topoisomerase II beta (TOP2β) instead of RNA polymerase 1. The study highlights the need for close monitoring of patients enrolled in ongoing clinical trials.
Researchers at West Virginia University have received FDA approval for a new drug to treat uveal melanoma, a rare form of eye cancer. The drug, MTI-201, targets specific biomarkers in diseased cells, allowing for more precise treatment with minimal damage to healthy cells.
Researchers at Johns Hopkins Kimmel Cancer Center found a new treatment option for inoperable pleural mesothelioma using immunotherapy agent durvalumab combined with platinum-based chemotherapy. Patients with epithelioid tumors experienced higher survival rates, including some who remained tumor-free after completing the trial.